Literature DB >> 25308178

HBeAg-positive chronic hepatitis B patients with prior long-time exposure to nucleos(t)ide analogues: "switch-to" or "add-on" PegIFN alfa, that is the question.

Shaolong Chen1, Wenhong Zhang2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25308178     DOI： 10.1016/j.jhep.2014.08.056

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  2 in total

1.  Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment.

Authors:  Guo-Jun Li; Yi-Qi Yu; Shao-Long Chen; Ping Fan; Ling-Yun Shao; Jia-Zhen Chen; Chang-Shui Li; Bin Yi; Wei-Cun Chen; Shu-Yuan Xie; Xiao-Na Mao; He-Hui Zou; Wen-Hong Zhang
Journal:  Antimicrob Agents Chemother       Date:  2015-05-04       Impact factor: 5.191

2.  Antiviral treatment for treatment-naïve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials.

Authors:  William W L Wong; Petros Pechivanoglou; Josephine Wong; Joanna M Bielecki; Alex Haines; Aysegul Erman; Yasmin Saeed; Arcturus Phoon; Mina Tadrous; Mona Younis; Noha Z Rayad; Valeria Rac; Harry L A Janssen; Murray D Krahn
Journal:  Syst Rev       Date:  2019-08-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.